A UK based two-centre review of multifocality and its role in the treatment of papillary thyroid cancer

•The significance of multifocality, particularly as a sole risk factor, in the management of papillary thyroid cancer (PTC) is unclear•Patients have excellent outcomes where multifocality is the only potential adverse risk factor (T1/2N0 disease)•Clinicians should take an individualised approach to treatment that balances a small chance of oncological benefit with the risks for harm associated with further surgery, with or without radioactive iodine, if multifocal disease is identified